ArticleScientific reports2026
Evaluation of cerebral blood flow and glymphatic function in acute mountain sickness by MRI ASL and DTI ALPS.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
To investigate alterations in glymphatic system function and cerebral blood flow (CBF) in individuals with acute mountain sickness (AMS), and to determine the relationship between these imaging findings and clinical symptom severity using diffusion tensor imaging along the perivascular space (DTI-ALPS) and three-dimensional arterial spin labeling (3D-ASL).Forty-one participants who rapidly ascended to high altitude were prospectively enrolled and divided into an AMS group (n = 21) and a non-AMS group (n = 20). All underwent DTI and 3D-ASL MRI sequences. The ALPS index and CBF values were measured, compared between groups, and correlated with Lake Louise AMS Scores (LLS). No significant difference was found in the ALPS index between the AMS and non-AMS groups (P > 0.05). However, the mean ALPS index showed a significant negative correlation with LLS (r = − 0.523, P < 0.001). In contrast, CBF was significantly higher in the cerebral cortex and white matter of the AMS group compared to the non-AMS group (P < 0.05). A weak but significant positive correlation was found between CBF in the corpus callosum and LLS (r = 0.322, P = 0.046). While glymphatic function, as measured by the ALPS index, correlates with AMS severity, it does not significantly differ between AMS and non-AMS groups. Elevated CBF in white matter and cerebral cortex, particularly in the corpus callosum, may serve as a potential imaging biomarker of AMS, underscoring the value of 3D-ASL for non-invasive assessment of cerebral perfusion changes in high-altitude conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.